The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a more substantial loss in body weight and improve metabolic markers, particularly